NCT04934059 is a Phase 4 clinical trial of Yuxuebi tablet in Ankylosing Spondylitis, sponsored by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd..

Who is sponsoring NCT04934059?

NCT04934059 is sponsored by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd..

What drugs are being tested in NCT04934059?

Interventions in NCT04934059: Yuxuebi tablet, Placebo tablet.

What condition does NCT04934059 study?

NCT04934059 studies Ankylosing Spondylitis.

Is NCT04934059 still recruiting?

NCT04934059 is currently status unknown. Last updated 22 June 2021.

Last reviewed 2021-06-22 · How we verify

NCT04934059

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis (AS).

Status unknown Phase 4 Last updated 22 June 2021

What this trial tests

Phase 4 trial testing Yuxuebi tablet in Ankylosing Spondylitis in 60 participants. Status unknown.

Timeline

1 July 2021

Primary endpoint
31 January 2022

31 January 2022

Quick facts

Lead sponsor	China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	1 July 2021
Primary completion	31 January 2022
Estimated completion	31 January 2022
Sites	5 locations across China

Drugs / interventions tested

Yuxuebi tablet — full drug profile →
Placebo tablet

Conditions studied

Ankylosing Spondylitis — all drugs for Ankylosing Spondylitis →

Sponsor

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 65, any sex, with Ankylosing Spondylitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Yuxuebi tablet in treating night pain of Ankylosing Spondylitis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Exploring the role of Yuxuebi tablet in neuropathic pain with the method of similarity research of drug pharmacological effects based on unsupervised machine learning.
Du X, Zhao C, Xi Y, Lin P, et al · · 2024 · PMID 39355777 · DOI 10.3389/fphar.2024.1440542

Verify or expand the search:

Other recruiting trials for Ankylosing Spondylitis

Currently open trials in the same condition.

NCT07510789 — Impact of Low Back Pain Phenotypes on Function and Quality of Life in Ankylosing Spondylitis · recruiting
NCT07261644 — A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) · Phase 3 · recruiting
NCT07390929 — Clinical Trial Study on the Improved New Method of Acupotomy for AS · NA · recruiting
NCT06905288 — Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea. · recruiting
NCT07166874 — The Impacts of Gluten-free Diet in Patients With Ankylosing Spondylitis · NA · recruiting

Other China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT05113888 — Exploratory Study on Dosage of Qizhi Weitong Granules in the Treatment of Irritable Bowel Syndrome （IBS) · Phase 2 · unknown
NCT05098990 — Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC · Phase 4 · unknown
NCT05249244 — A Real World Study of the Treatment of Gastric Adenocarcinoma With Huachansu · unknown
NCT02135835 — A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04934059 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Last refreshed: 22 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04934059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing